(firstQuint)Pharmacokinetics of 20 mg Teduglutide in Subjects With Moderately Impaired Hepatic Function Compared to Healthy Subjects With Normal Hepatic Function.

 24 subjects (equally divided between subjects with normal hepatic function and those with moderate hepatic impairment (defined by the protocol as a Child-Pugh classification of grade B score of 7-9)will be given a single injection of teduglutide (20mg) through subcutaneous injection into the abdomen.

 Blood samples would be taken within 30 minutes of dose through 24 hours post-dose.

 Subjects in both groups are matched up by sex, age, BMI, and renal function.

.

 Pharmacokinetics of 20 mg Teduglutide in Subjects With Moderately Impaired Hepatic Function Compared to Healthy Subjects With Normal Hepatic Function@highlight

This is a study to compare the pharmacokinetic profile of teduglutide in healthy subjects with normal hepatic function with subjects who have moderate hepatic impairment.

